ArticleHuman vaccines & immunotherapeutics2020
Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017.
Article in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Clinical epidemiology of herpes zoster and postherpetic neuralgia in Barcelona (Spain). A single-center study.Frontiers in public health · 2026Article
- Adverse events following measles, mumps, rubella and varicella virus vaccine live (PROQUADVirology journal · 2025Article
- Challenging 21-day quarantine guidelines for mumps in Beijing: Data-driven recommendations for a high-coverage MMR vaccination era (2019-2024).Human vaccines & immunotherapeutics · 2025Article
- Evaluation and optimization of mumps-containing vaccination strategies: a study based on an individual-based stochastic model.EClinicalMedicine · 2025Article
- Determinants of Hospital Length of Stay in Herpes Zoster Patients: A Four-Year Retrospective Study.Health science reports · 2025Article
- Vaccine hesitancy in adolescents regarding COVID-19 vaccination: A literature review.Vaccine: X · 2024Review
- Article
- Real-World Effectiveness of the Varicella Vaccine among Children and Adolescents in Qatar: A Case-Control Study.Vaccines · 2023Article
- Two years of on-site influenza vaccination strategy in an Italian university hospital: main results and lessons learned.Human vaccines & immunotherapeutics · 2022Article
- Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018-2020.Human vaccines & immunotherapeutics · 2022Observational
- Stimulated Reporting of Adverse Events Following Immunization with COVID-19 Vaccines.Vaccines · 2022Article
- Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: A descriptive analysis from VigiAccess.Human vaccines & immunotherapeutics · 2022Article
- Comparison of varicella outbreaks in schools in China during different vaccination periods.Human vaccines & immunotherapeutics · 2022Article
- Article
- Attitude for vaccination prophylaxis among pregnant women: a cross-sectional study.Human vaccines & immunotherapeutics · 2022Article
- Article
- Long -term persistence of antibodies against varicella in fully immunized healthcare workers: an Italian retrospective cohort study.BMC infectious diseases · 2021Article
- Article
- Adverse events following measles-mumps-rubella-varicella vaccine: an independent perspective on Italian pharmacovigilance data.F1000Research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since 2006, some Italian Regions introduced the active offer of measles, mumps, rubella, and varicella (MMRV) vaccine for all newborns during the second years of life. In 2011, Italian Drug Authority (AIFA) recommended the discontinuation of the MMRV use for an increased risk of febrile seizures following vaccination; furthermore, some Regions (such as Apulia, that introduced MMRV offer in 2009) chose to continue the use of MMRV and Ministry of Health recommended to guarantee supplemental monitoring of safety of the vaccine. In Italy, the surveillance of Adverse Events following immunization (AEFIs) is currently carried out by AIFA and Regional Health Authorities; this paper aims to summarize the results of MMRV-vaccine surveillance of AEFIs program carried out in Apulia. From the AIFA database, we selected MMRV AEFIs that occurred in Apulia (about 4,000,000 inhabitants) from 2009 to 2017. For serious AEFIs, we applied the WHO causality assessment algorithm, using for cases hospitalized information from individual medical records. In the 8 years of observation, 155 MMRV-AEFIs (reporting rate: 37.9×100,000 doses) occurred of which 26 were classified as serious (6.3×100,000 doses) and 22 led to hospitalization. Performing causality assessment, for 10 the classification was "consistent causal association to immunization" (reporting rate: 2.4×100000 doses), for 2 indeterminate, for 13 "inconsistent causal association to immunization" and for 1 not-classifiable. No case of febrile seizure resulted consistent to vaccination. All consistent serious AEFIs were completely resolved at subsequent follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.